Loading clinical trials...

Efficacy Study of Dietary Intervention and Weight Loss in Improving Psoriasis | Clinical Trials | Clareo Health

COMPLETEDNA

Efficacy Study of Dietary Intervention and Weight Loss in Improving Psoriasis

Multicenter Randomized Clinical Study Evaluating the Efficacy of Dietary Intervention and Weight Loss in Improving Psoriasis

NCT01714284•Centro Studi Gised

View on ClinicalTrials.gov

Summary

This is a multicenter randomized controlled clinical trial evaluating the impact of a structured non pharmacological intervention consisting in intensive weight reduction (qualitative and quantitative changes in diet associated with physical exercise) compared to an intervention based on a simple informative counseling about the utility of weight loss for clinical control of psoriatic disease.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of chronic plaque psoriasis
•BMI \> 25 Kg/m²
•Patients under systemic treatments for psoriasis or candidates for such treatments

Exclusion Criteria

•Diagnosis of other type of psoriasis or psoriatic arthritis
•Patients under local treatments or candidates for such treatments
•Patients expected to have poor compliance at follow-up evaluation

Locations (11)

Department of Dermatology; Bellaria-Maggiore Hospital

Bologna, Emilia-Romagna, Italy

Department of Dermatology; S.Orsola-Malpighi General Hospital

Bologna, Emilia-Romagna, Italy

Dermatology Department; M. Bufalini Hospital

Cesena, Emilia-Romagna, Italy

Department of Dermatology; S. Anna University Hospital

Ferrara, Emilia-Romagna, Italy

Department of Dermatology; G.B.Morgagni-L.Pierantoni Hospital

Forlì, Emilia-Romagna, Italy

Department of Dermatology; University General Hospital of Modena

Modena, Emilia-Romagna, Italy

Department of Dermatology; University General Hospital of Parma

Parma, Emilia-Romagna, Italy

Department of Dermatology; Hospital of Piacenza

Piacenza, Emilia-Romagna, Italy

Department of Dermatology; AUSL of Ravenna

Ravenna, Emilia-Romagna, Italy

Department of Dermatology; S. Maria Nuova Hospital

Reggio Emilia, Emilia-Romagna, Italy

Key Dates

Start Date

February 1, 2011

Primary Completion Date

January 1, 2012

Completion Date

January 1, 2012

Last Updated

February 22, 2013

Enrollment

303

ACTUAL participants

Conditions

Psoriasis

Interventions

Informative

BEHAVIORAL

Diet and Exercise

BEHAVIORAL

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

NCT07449234

Psoriasis

View study

RECRUITINGPHASE3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967

Plaque Psoriasis

View study

RECRUITINGPHASE3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 22, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy Study of Dietary Intervention and Weight Loss in Improving Psoriasis

Inclusion Criteria

Exclusion Criteria

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Real-Life Evaluation of Guselkumab Dosing Interval Adjustments